Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1956 1
1957 1
1958 2
1960 2
1961 1
1994 1
1995 1
1996 9
1997 21
1998 16
1999 20
2000 31
2001 44
2002 66
2003 74
2004 77
2005 96
2006 83
2007 89
2008 85
2009 94
2010 91
2011 95
2012 82
2013 87
2014 90
2015 72
2016 62
2017 69
2018 50
2019 26
2020 4
Text availability
Article attribute
Article type
Publication date

Search Results

1,386 results
Results by year
Filters applied: . Clear all
Page 1
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
Mehta RS, et al. N Engl J Med 2019 - Clinical Trial. PMID 30917258 Free PMC article.
METHODS: We randomly assigned patients to receive either anastrozole or fulvestrant plus anastrozole. Randomization was stratified according to adjuvant tamoxifen use. ...Approximately 45% of the patients in the anastrozole-alone group crossed over to receive fulvestrant. CONCLUSIONS: The addition of fulvestrant to anastrozole was associated with increased long-term survival as compared with anastrozole alone, despite substantial crossover to fulvestrant after progression during therapy with anastrozole alone. ...
METHODS: We randomly assigned patients to receive either anastrozole or fulvestrant plus anastrozole. Randomization was strati …
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Cuzick J, et al. Lancet Oncol 2010 - Clinical Trial. PMID 21087898
After treatment completion, we continued to collect data on fractures and serious adverse events in a masked fashion (safety population: anastrozole n=3092, tamoxifen n=3094). ...Treatment-related serious adverse events were less common in the anastrozole group than the tamoxifen group (223 anastrozole vs 369 tamoxifen; OR 0·57, 95% CI 0·48-0·69; p<0·0001), but were similar after treatment completion (66 vs 78; OR 0·84, 95% CI 0·60-1·19; p=0·3). ...
After treatment completion, we continued to collect data on fractures and serious adverse events in a masked fashion (safety population: …
Pharmacokinetic evaluation of a transdermal anastrozole-in-adhesive formulation.
Regenthal R, et al. Drug Des Devel Ther 2018. PMID 30464397 Free PMC article.
In contrast, a sustained-release system for the local application of anastrozole should minimize these serious adverse drug reactions. ...In vitro continuous anastrozole release profiles were studied in Franz diffusion cells. In vivo, consecutive drug plasma kinetics from the final anastrozole transdermal system was tested in beagle dogs. ...
In contrast, a sustained-release system for the local application of anastrozole should minimize these serious adverse drug reactions …
Effects of psoralen on the pharmacokinetics of anastrozole in rats.
Zhang Y, et al. Pharm Biol 2018. PMID 30345900 Free PMC article.
CONTEXT: Psoralen and anastrozole are always used together for breast cancer patients in Chinese clinics. OBJECTIVE: This study investigates the effects of psoralen on the pharmacokinetics of anastrozole in rats and its potential mechanism. ...The plasma concentration of anastrozole was determined using a sensitive and reliable LC-MS/MS method. Additionally, the effects of psoralen on the intestine transport and metabolic stability of anastrozole (1 μM) were investigated using a Caco-2 cell transwell model and rat liver microsome incubation systems. ...
CONTEXT: Psoralen and anastrozole are always used together for breast cancer patients in Chinese clinics. OBJECTIVE: This study inves …
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S, et al. Lancet Oncol 2018 - Clinical Trial. PMID 29482983
BACKGROUND: Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole. ...Patients were randomly assigned in an equal ratio to one of six treatment groups: oral anastrozole (1 mg per day), exemestane (25 mg per day), or letrozole (2·5 mg per day) tablets upfront for 5 years (upfront strategy) or oral tamoxifen (20 mg per day) for 2 years followed by oral administration of one of the three aromatase inhibitors for 3 years (switch strategy). ...
BACKGROUND: Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowl …
Combination therapy with clomiphene citrate and anastrozole is a safe and effective alternative for hypoandrogenic subfertile men.
Alder NJ, et al. BJU Int 2018. PMID 29873446 Free article.
OBJECTIVES: To assess the efficacy and safety of combination therapy with clomiphene citrate (CC) and anastrozole (AZ) for male hypoandrogenism. ...
OBJECTIVES: To assess the efficacy and safety of combination therapy with clomiphene citrate (CC) and anastrozole (AZ) for male hypoa …
Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer.
Robertson JFR, et al. Eur J Cancer 2018 - Clinical Trial. PMID 29574365 Free article.
METHODS: Women with endocrine therapy-naïve HR+ LA/MBC were randomised 1:1 to fulvestrant (days 0, 14, 28, then every 28 d) or anastrozole (daily) until disease progression or discontinuation. ...RESULTS: In total, 462 patients were randomised (fulvestrant, n = 230; anastrozole, n = 232). Compliance to FACT-B overall ranged from 60.0 to 97.4%. ...
METHODS: Women with endocrine therapy-naïve HR+ LA/MBC were randomised 1:1 to fulvestrant (days 0, 14, 28, then every 28 d) or anastrozol
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
Sestak I, et al. JAMA Oncol 2018 - Clinical Trial. PMID 29450494 Free PMC article.
This analysis was performed as a preplanned secondary study of data from the Anastrozole or Tamoxifen Alone or Combined randomized clinical trial comparing 5-year treatment with anastrozole vs tamoxifen with 10-year follow-up data. ...
This analysis was performed as a preplanned secondary study of data from the Anastrozole or Tamoxifen Alone or Combined randomized cl …
1,386 results
Jump to page
Feedback